References
- Kaasa S, Loge JH, Aapro M, et al. Integration of oncology and palliative care: a lancet oncology commission. Lancet Oncol 2018;19:E588–653.
- Holohan C, Schaeybroeck SV, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714–26.
- (a) Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423–35. (b) Mckeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010;116:1859–71.
- Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009;15:2594–601.
- Liu ZP, Liu YN, Ji YT. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments. Curr Med Chem 2015;22:1348–60.
- Porcu E, Bortolozzi R, Basso G, Viola G. Recent advances in vascular disrupting agents in cancer therapy. Future Med Chem 2014;6:1485–98.
- Kanthou C, Tozer GM. The tumor vascular targeting agent Combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060–9.
- Ducki S, Rennison D, Woo M, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. Bioorg Med Chem 2009;17:7698–710.
- Zweifel M, Jayson GC, Reed N, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22:2036–41.
- Zhuang C, Zhang W, Sheng C, et al. Chalcone: a privileged structure in medicinal chemistry. Chem Rev 2017;117:7762–810.
- Yan J, Chen J, Zhang S, et al. Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo. J Med Chem 2016;59:5264–83.
- Canela MD, Noppen S, Bueno O, et al. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091. Oncotarget 2017;8:14325–42.
- Saito Y, Mizokami A, Izumi K, et al. α-Trifluoromethyl chalcones as potent anticancer agents for androgen receptor-independent prostate cancer. Molecules 2021; 26:2812.
- Liu YZ, Wang XL, Wang XY, et al. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach. J Mol Model 2016;22:1–8.
- (a) Sun MR, Zhang YX, Qin JL, et al. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: potent inhibitors of angiogenesis and tubulin polymerization. Bioorg Chem 2021;113:104988. (b) Wang YG, Sun MR, Wang YY et al. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency. Eur J Med Chem 2021;225:113790.
- Díaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747–55.
- Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted antimitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107–17.
- Afshari CA, Barrett JC. Cell cycle controls: potential targets for chemical carcinogens? Environ Health Persp 1993;101:9–14.
- Jackman M, Lindon C, Nigg EA, Pines J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 2003;5:143–8.
- Hensley P, Mishra M, Kyprianou N. Targeting caspases in cancer therapeutics. Biol Chem 2013;394:831–43.
- Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81–6.
- Shi YW, Yuan W, Wang X, et al. Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish. Sci Rep-UK 2016;6:30189.